Centipeda minima extract composition for autoimmune disease treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and non-alcoholic fatty liver disease, such as those using synthetic JAK inhibitors like tofacitinib, are associated with significant side effects and limited accessibility, while traditional extraction methods for active compounds from Centipeda minima are inefficient and costly.
Innovation Solution
A composition derived from Centipeda minima, comprising Brevilin A, Arnicolide D, Arnicolide C, and Microhelenin C, which inhibits JAK-STAT signaling and cytokine interactions, and is extracted using a novel phase separation method, enhancing extraction efficiency and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic JAK inhibitors like tofacitinib are used to treat autoimmune diseases, then immune suppression and inflammatory response inhibition are achieved, but numerous side effects including serious infections, intestinal perforation, elevated cholesterol, and high cost occur
Solution Approach 1:
The patent replaces expensive synthetic JAK inhibitors with a natural extract from Centipeda minima that contains multiple active compounds working synergistically. This natural composition provides comparable immunosuppressive and anti-inflammatory effects without the severe side effects and high costs associated with synthetic drugs like tofacitinib
Solution Approach 2:
The patent utilizes a composite natural extract containing multiple active compounds (brevilin A, arnicolide C, arnicolide D, microhelenin C, and other sesquiterpene lactones) from Centipeda minima. This composite composition provides synergistic therapeutic effects that address both treatment efficacy and safety concerns better than single synthetic compounds
2Quantity of substance
If traditional liquid-liquid extraction methods are used to extract active compounds from Centipeda minima, then some active ingredients are obtained, but the extraction process is highly inefficient, complicated, lengthy, and costly due to multiple repeated extractions and drying processes
Solution Approach 1:
The patent employs supercritical fluid extraction to efficiently extract active compounds from Centipeda minima. This method selectively extracts desired compounds while leaving behind unwanted materials, achieving high extraction yield without the inefficiencies of traditional multi-step liquid-liquid extraction and drying processes
Solution Approach 2:
The patent replaces the complex mechanical and chemical extraction system (multiple liquid-liquid extractions, filtrations, and drying steps) with a streamlined supercritical fluid extraction system. This substitution dramatically reduces process complexity, time, and cost while maintaining or improving extraction efficiency
Data Source
AI summary
Disclosed is a composition for preventing and treating anti-inflammatory and autoimmune diseases and non-alcoholic fatty liver disease, wherein the composition for preventing and treating anti-inflammatory and autoimmune diseases and non-alcoholic fatty liver disease according to an embodiment of the present invention includes an extract of Centipeda minima extract including, as an active ingredient, at least one selected from the group consisting of Brebilin A, Arnicolide D, Arnicolide C, and Microhelenin C.